By Fineline Cube C4 Therapeutics, Inc. (NASDAQ: CCCC), a leader in targeted protein degradation (TPD), announced an expanded strategic collaboration with Roche AG (SWX: ROG; OTCMKTS: RHHBY) to co-develop degrader-antibody conjugates (DACs)—a novel therapeutic modality merging the precision of antibody-drug conjugates (ADCs) with the catalytic power of small-molecule degraders. The partnership targets two undisclosed oncology indications, with an option for a third, and includes up to over USD 1 billion in potential milestone payments plus tiered royalties for C4T.
Deal Structure & Responsibilities
| Component | C4 Therapeutics | Roche |
|---|---|---|
| Technology Contribution | Proprietary TORPEDO® degrader platform for payload design | Antibody discovery, conjugation, and ADC engineering |
| Development Scope | Design of degrader payloads against two proprietary targets | Full preclinical/clinical development and global commercialization |
| Financial Terms | $20M upfront + near-term discovery milestones | Option fee for third target + regulatory/commercial milestones |
| Total Potential Value | > $1 billion across discovery, regulatory, and sales milestones | — |
| Royalties | Tiered, single-digit to low-teens % on net sales (subject to reductions) | — |
This marks one of the first industry-wide efforts to systematically integrate PROTAC-like degraders into antibody-conjugate architectures, potentially overcoming key limitations of traditional ADCs—such as payload resistance and limited bystander effect—through catalytic, event-driven target elimination.
Scientific Rationale: Why DACs?
- Enhanced Potency: Degraders act catalytically (one molecule can eliminate multiple target proteins), enabling lower dosing vs. stoichiometric payloads
- Broader Target Scope: DACs can address “undruggable” intracellular oncoproteins previously inaccessible to antibodies
- Improved Therapeutic Index: Antibody-mediated tumor targeting minimizes systemic exposure of potent degraders
- Resistance Mitigation: Protein degradation removes entire functional units, reducing escape via point mutations
The TORPEDO platform enables rapid optimization of degrader pharmacokinetics, stability, and linker compatibility—critical for successful conjugation to monoclonal antibodies.
Strategic Implications
- Roche’s ADC Leadership: Builds on Roche’s established ADC expertise (e.g., Polivy®, Enhertu® co-development) while future-proofing its oncology pipeline
- C4T’s Platform Validation: Demonstrates strong pharma confidence in TPD beyond oral small molecules
- Market Timing: Positions DACs as next-generation successors to conventional ADCs amid intense competition in solid tumors
- Pipeline Acceleration: Roche’s global development engine could fast-track DAC candidates into IND-enabling studies within 18–24 months
Forward-Looking Statements
This brief contains forward-looking statements regarding collaboration execution, milestone achievement, and clinical potential. Actual outcomes depend on scientific feasibility, regulatory approvals, and market dynamics.-Fineline Info & Tech